Health
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.
About this update from Lunit Inc.
[{"type":"text","content":"Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care","length":147,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.","length":533,"tagName":"p"},{"type":"image","alt":"Lunit and the National Cancer Institute (NCI) join forces to advance AI-powered biomarker research and accelerate personalized cancer care.","displaySize":"","headline":null,"caption":"Lunit and the National Cancer Institute (NCI) join forces to advance AI-powered biomarker research and accelerate personalized cancer care.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":222,"url":"https://media.zenfs.com/en/prnewswire.com/1b2c0c6c6d0304ad8e16fe5d3a87b398"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nggQg7Xssv9BzADAlPpB9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1b2c0c6c6d0304ad8e16fe5d3a87b398","width":400,"height":222}},"href":"https://mma.prnewswire.com/media/2653751/Lunit_National_Cancer_Institute__NCI__join_forces_advance_AI_powered_biomarker.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.","length":451,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Lunit)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Lunit)","className":"","disableSlideshowImg":false,"size":{"original":{"widt...